ProCE Banner Activity

Overview and Rationale for Targeting TRK Fusions in Solid Tumors

Slideset Download
In this downloadable slideset, George D. Demetri, MD, provides an overview on the biology of NTRK fusions in patients with cancer and the rationale for using TRK inhibitors in clinical practice.

Released: June 04, 2019

Expiration: June 02, 2020

No longer available for credit.

Share

Faculty

George D. Demetri

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts